Haemonetics Shares Up 8.88%; Earlier, Co. Reported Q2 Adj. EPS $0.48 vs $0.41 Est., Sales $225M vs $219.26M Est.; Co. Raised FY18 Outlook, Adj. EPS From $1.55-$1.65 to $1.65-$1.75 vs $1.61 Est., Sales Appox. Flat With FY17
Hal Lindon